Tran A, Benzaken S, Braun H B, Fredenrich A, Dreyfus G, Durant J, Hiéronimus S, Quaranta J F, Ouzan D, Michel G
Department of Gastroenterology and Hepatology, Hôpital de l'Archet, Nice, France.
Clin Immunol Immunopathol. 1995 Nov;77(2):127-30. doi: 10.1006/clin.1995.1135.
Anti-thyroid autoantibodies have been described in anti-hepatitis C virus (HCV)-positive patients. It has been suggested that the anti-GOR response is closely related to HCV infection and may reflect an HCV-associated autoimmune phenomenon. This study was designed to evaluate the humoral anti-GOR response in anti-HCV-positive patients with anti-thyroid autoantibodies (group 1, 22 patients) and to compare it with the response in anti-HCV-positive patients without anti-thyroid autoantibodies (group 2, 44 patients) and in anti-HCV-negative patients with autoimmune thyroiditis (group 3, 28 patients). The prevalences of anti-GOR in groups 1, 2, and 3 were, respectively, 72.7, 61.3, and 3.5%. Anti-GOR levels were higher in group 1 than in group 2 or group 3 (P = 0.0001). Moreover, comparison of the Anti-GOR levels of groups 1 and 2 also revealed a statistically significant difference (P = 0.008). Detection of more elevated anti-GOR levels in group 1 patients suggests that anti-thyroid autoantibodies in anti-HCV-positive patients may be related to HCV.
抗甲状腺自身抗体已在抗丙型肝炎病毒（HCV）阳性患者中被描述。有人提出，抗GOR反应与HCV感染密切相关，可能反映了一种与HCV相关的自身免疫现象。本研究旨在评估抗甲状腺自身抗体阳性的抗HCV阳性患者（第1组，22例患者）的体液抗GOR反应，并将其与无抗甲状腺自身抗体的抗HCV阳性患者（第2组，44例患者）和自身免疫性甲状腺炎的抗HCV阴性患者（第3组，28例患者）的反应进行比较。第1、2和3组中抗GOR的患病率分别为72.7%、61.3%和3.5%。第1组的抗GOR水平高于第2组或第3组（P = 0.0001）。此外，第1组和第2组抗GOR水平的比较也显示出统计学上的显著差异（P = 0.008）。第1组患者中检测到更高的抗GOR水平表明，抗HCV阳性患者中的抗甲状腺自身抗体可能与HCV有关。
